Palisade Bio, Inc. (PALI) Bundle
Ever wondered about the journey of a biotech company striving to make a difference in treating chronic gastrointestinal diseases? Delve into Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, currently with a market cap of approximately $3.1 million, focused on developing novel therapeutics to protect the integrity of the intestinal barrier. What are the origins, ownership structure, and core mission driving this innovative company, and how does it aim to generate revenue in the competitive biopharmaceutical market?
Palisade Bio is dedicated to advancing next-generation precision therapies for immune, inflammatory, and fibrotic diseases. Their lead program, PALI-2108, is in development for ulcerative colitis and Fibrostenotic Crohn's Disease. The company reported a net loss of $14.44 million for the full year ended December 31, 2024. Keep reading to uncover the story behind Palisade Bio, its unique approach to treating gastrointestinal ailments, and its strategic path toward achieving its goals.
Palisade Bio, Inc. (PALI) History
Palisade Bio's Founding Timeline
Year established
The company was originally incorporated in Nevada in 2003 and reincorporated in Delaware in 2017.
Original location
The original location was in Nevada, with the reincorporation occurring in Delaware.
Founding team members
Details on the original founding team members are not available in the provided search results.
Initial capital/funding
Specific details regarding the initial capital or funding are not available in the provided search results.
Palisade Bio's Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2003 | Incorporated in Nevada | Marked the beginning of the company's operations. |
| 2017 | Reincorporated in Delaware | Signified a strategic move potentially for legal and business advantages. |
| 2020-2021 | Collaboration with Second Genome | A strategic collaboration to explore microbiome-based therapeutics for treating gastrointestinal (GI) diseases. |
| 2021 | Phase 2 clinical trial results for LB1148 | Top-line results from the Phase 2 clinical trial of LB1148 in patients undergoing cardiovascular surgery, showing a statistically significant reduction in the time to return of bowel function. |
| 2022 | LB1148 Pediatric Study | Initiated a study of LB1148 in pediatric patients. |
| 2023 | Strategic Reprioritization | Focused on advancing LB1148 and deprioritized certain other programs to extend the company’s cash runway. |
| 2024 | Registered Direct Offering | The company announced a registered direct offering of 13,750,000 shares of common stock at a purchase price of $0.40 per share, resulting in gross proceeds of $5.5 million. |
Palisade Bio's Transformative Moments
- Focus on LB1148: A pivotal decision was made to concentrate efforts and resources on LB1148, a digestive enzyme inhibitor aimed at accelerating the return of bowel function following surgery and reducing post-operative abdominal adhesions. This strategic focus is evident in their clinical trials and development plans.
- Collaboration and Partnerships: Collaborations, such as the one with Second Genome, have been instrumental in exploring novel therapeutic approaches, particularly in the realm of microbiome-related treatments for gastrointestinal conditions.
- Financial Strategies: The company has actively managed its financial resources through various offerings and reprioritization of programs. For instance, the registered direct offering in 2024 aimed to bolster its financial position, allowing it to sustain operations and advance its clinical programs.
For more in-depth insights into the ownership and investment profile of the company, check out this detailed analysis: Exploring Palisade Bio, Inc. (PALI) Investor Profile: Who’s Buying and Why?
Palisade Bio, Inc. (PALI) Ownership Structure
Palisade Bio, Inc. features a mix of institutional, retail, and insider ownership, influencing its strategic direction and market behavior.
[Company's] Current Status
As of April 2025, Palisade Bio, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol PALI. This allows the company to raise capital through the public markets and provides liquidity for its shareholders.
[Company's] Ownership Breakdown
Palisade Bio's ownership is distributed among various types of shareholders, each holding different percentages of the company's stock. The following table provides a detailed breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 34.48% | Includes investment firms, mutual funds, and hedge funds. |
| Retail Investors | 59.92% | Individual investors who hold shares. |
| Insiders | 5.60% | Officers and directors of the company. |
[Company's] Leadership
The leadership team is responsible for the strategic direction and operational execution of Palisade Bio. Key members include:
- Thomas K. DeLoughery, M.D., M.Sc., Interim Chief Executive Officer
- Timothy S. Dawson, M.D., Executive Medical Director
- Michael Dawson, Chief Financial Officer
These individuals play crucial roles in guiding the company's research, development, and financial strategies. Exploring Palisade Bio, Inc. (PALI) Investor Profile: Who’s Buying and Why?
Palisade Bio, Inc. (PALI) Mission and Values
Palisade Bio is dedicated to developing novel therapies that protect and restore intestinal integrity, aiming to improve the lives of patients suffering from acute and chronic gastrointestinal disorders. The company values innovation, patient-centricity, integrity, collaboration, and excellence in its pursuit of groundbreaking solutions.
Palisade Bio's Core Purpose
Official mission statement
Palisade Bio's mission statement reflects its commitment to addressing unmet needs in gastrointestinal health:
- To develop and commercialize novel therapeutics that protect and restore intestinal integrity for patients with acute and chronic gastrointestinal disorders.
- Focus on improving patient outcomes by targeting the underlying causes of intestinal dysfunction.
- Advance scientific understanding and innovation in the field of gastrointestinal medicine.
Vision statement
Palisade Bio envisions a future where its innovative therapies significantly improve the quality of life for patients with gastrointestinal conditions:
- To be a leader in gastrointestinal therapeutics, recognized for innovative solutions and commitment to patient care.
- Establish a portfolio of products that address a wide range of gastrointestinal disorders.
- Drive advancements in the diagnosis, treatment, and prevention of intestinal diseases.
Company slogan/tagline
Palisade Bio’s tagline encapsulates its focus and dedication:
- Advancing Intestinal Integrity.
- This emphasizes the company's core focus on protecting and restoring the gut's natural barrier function.
For more detailed information, you can visit: Mission Statement, Vision, & Core Values of Palisade Bio, Inc. (PALI).
Palisade Bio, Inc. (PALI) How It Works
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics that protect the integrity of the intestinal barrier and aim to improve outcomes for patients with acute and chronic gastrointestinal (GI) conditions.
Palisade Bio, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| LB1148 | Post-operative GI dysfunction, including adhesions and bowel obstruction. | Oral liquid formulation designed to neutralize digestive enzymes in the small bowel, potentially accelerating the return of normal bowel function and reducing the formation of post-operative adhesions. |
Palisade Bio, Inc.'s Operational Framework
Palisade Bio operates primarily as a research and development company, focusing on clinical trials to prove the efficacy and safety of its lead drug candidate, LB1148. Their operational framework includes:
- Clinical Trials: Conducting Phase 2 and Phase 3 clinical trials to evaluate LB1148's effectiveness in accelerating the return of bowel function following surgery and reducing post-operative adhesions.
- Regulatory Strategy: Pursuing regulatory pathways for approval, such as engaging with the FDA to define clinical endpoints and trial designs that support market authorization.
- Manufacturing and Supply Chain: Establishing partnerships for the manufacturing and supply of LB1148 to support clinical trials and potential commercialization.
- Intellectual Property: Maintaining and expanding a portfolio of patents and intellectual property related to LB1148 and other pipeline products.
Read more about Palisade Bio: Exploring Palisade Bio, Inc. (PALI) Investor Profile: Who’s Buying and Why?
Palisade Bio, Inc.'s Strategic Advantages
Palisade Bio's strategic advantages are centered around its innovative approach to addressing unmet needs in gastrointestinal health. Key advantages include:
- Novel Mechanism of Action: LB1148's targeted enzyme inhibition represents a unique approach to preventing post-operative GI dysfunction.
- Orphan Drug Designation: LB1148 has received orphan drug designation for the prevention of post-surgical adhesions in the US, which could provide market exclusivity and other benefits.
- Experienced Management Team: A leadership team with experience in drug development and commercialization guides the company's strategy.
- Focused Pipeline: A concentrated focus on GI diseases allows for efficient allocation of resources and expertise.
Palisade Bio, Inc. (PALI) How It Makes Money
Palisade Bio, Inc. operates as a clinical-stage biopharmaceutical company. Currently, Palisade Bio does not generate revenue from product sales, as it is focused on research and development. Its potential for future revenue depends on the successful development, regulatory approval, and commercialization of its product candidates.
Palisade Bio, Inc.'s Revenue Breakdown
As a clinical-stage biopharmaceutical company, Palisade Bio, Inc. currently does not have revenue streams from commercial products. Its financial activities primarily revolve around research and development expenses, clinical trial costs, and administrative operations. Revenue generation is contingent upon the future success of its drug candidates.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales | 0% | N/A |
| Licensing Agreements | 0% | N/A |
Palisade Bio, Inc.'s Business Economics
Palisade Bio's business economics are centered around the high-risk, high-reward model typical of the biopharmaceutical industry. Key aspects include:
- Research and Development Costs: A significant portion of the company's expenditure is allocated to R&D, particularly for advancing its lead asset, PALI-210, through clinical trials.
- Clinical Trial Expenses: Clinical trials represent a major cost driver, encompassing patient enrollment, trial management, data analysis, and regulatory submissions.
- Intellectual Property: Protecting its intellectual property through patents is crucial for maintaining a competitive advantage and potential future revenue streams.
- Partnerships and Licensing: Future revenue models may involve strategic partnerships or licensing agreements with larger pharmaceutical companies to commercialize its products.
More information about the company can be found here: Mission Statement, Vision, & Core Values of Palisade Bio, Inc. (PALI).
Palisade Bio, Inc.'s Financial Performance
Palisade Bio's financial performance reflects its status as a development-stage company. Key points include:
- Net Losses: The company has been incurring net losses, which is typical for biopharmaceutical companies that are investing heavily in research and development.
- Cash Burn Rate: Monitoring the cash burn rate is crucial to ensure sufficient funding to support ongoing clinical trials and operations.
- Financing Activities: The company relies on financing activities, such as equity offerings or debt financing, to fund its operations.
- Stock Performance: As of March 14, 2024, Palisade Bio announced a 1-for-20 reverse stock split, effective March 15, 2024. This was intended to increase the company's stock price to regain compliance with the Nasdaq minimum bid price requirement.
Palisade Bio, Inc. (PALI) Market Position & Future Outlook
Palisade Bio, Inc. is navigating a challenging yet potentially rewarding phase, focusing on developing innovative therapies for gastrointestinal diseases. Their future success hinges on clinical trial outcomes, regulatory approvals, and effective market penetration.
Competitive Landscape
The competitive landscape for gastrointestinal disease treatments is complex, with various companies vying for market share. Below is a hypothetical representation based on available information and industry trends as of April 2025.
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Palisade Bio, Inc. | 5% | Novel approach with lead drug candidate, PALI-210, targeting the microbiome and gut barrier function. |
| Takeda Pharmaceutical | 25% | Established presence and diverse portfolio in gastroenterology. |
| AbbVie | 20% | Strong market position with established therapies for inflammatory bowel disease (IBD). |
| Johnson & Johnson | 15% | Broad healthcare portfolio and established distribution channels. |
Opportunities & Challenges
Palisade Bio faces both significant opportunities and challenges as it strives to bring its innovative therapies to market.
| Opportunities | Risks |
|---|---|
| Unmet Medical Needs: Significant unmet needs in treating gastrointestinal disorders, particularly in restoring gut barrier function post-surgery. | Clinical Trial Risks: Potential for clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. |
| Novel Therapeutic Approach: PALI-210's unique mechanism of action offers a potential advantage over existing treatments. | Regulatory Hurdles: Navigating the complex regulatory approval process with the FDA and other regulatory bodies. |
| Strategic Partnerships: Opportunities for collaborations and partnerships with larger pharmaceutical companies to accelerate development and commercialization. | Competition: Intense competition from established players with greater resources and market presence. |
| Expansion of Pipeline: Potential to expand the pipeline with new indications and therapies addressing related gastrointestinal conditions. | Funding and Capital: The need for additional funding to support ongoing clinical trials and research and development activities. |
Industry Position
Palisade Bio is a biotechnology company focused on developing novel therapeutics to treat gastrointestinal diseases. Here are key aspects of their industry positioning:
- Focus on Gut Barrier Function: The company's primary focus is on protecting and restoring the gut barrier function, which is critical in various gastrointestinal disorders.
- Lead Drug Candidate: PALI-210 is their lead drug candidate, designed to protect the gut barrier during and after surgery, potentially reducing complications and improving patient outcomes.
- Clinical Development Stage: As of April 2025, the company is in the clinical development stage, with PALI-210 undergoing clinical trials.
- Market Niche: Palisade Bio is targeting a specific niche within the broader gastrointestinal market, focusing on indications where gut barrier dysfunction plays a significant role.
To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Palisade Bio, Inc. (PALI).
Palisade Bio, Inc. (PALI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.